Abstract
Semaphorins (Semas), a family of evolutionarily conserved secreted and transmembrane proteins, were initially identified as axon guidance regulators and have since been implicated in the development of a number of other tissues. Sema signaling also regulates a variety of processes that are linked to cancer (i.e. metastasis, cell migration, cell growth). The mechanisms by which Sema signaling regulates axonogenesis and tumorigenesis are strikingly similar, making advances in either field applicable to the alternate discipline. Here, recent advances in understanding the roles of Semas in development and cancer, as well as the therapeutic potential for targeting this signaling pathway in human cancers, are reviewed.
Keywords: Semaphorin, Plexin, axon guidance, cancer, development
Current Drug Targets
Title: Semaphorins at the Interface of Development and Cancer
Volume: 10 Issue: 7
Author(s): E. Flannery and M. Duman-Scheel
Affiliation:
Keywords: Semaphorin, Plexin, axon guidance, cancer, development
Abstract: Semaphorins (Semas), a family of evolutionarily conserved secreted and transmembrane proteins, were initially identified as axon guidance regulators and have since been implicated in the development of a number of other tissues. Sema signaling also regulates a variety of processes that are linked to cancer (i.e. metastasis, cell migration, cell growth). The mechanisms by which Sema signaling regulates axonogenesis and tumorigenesis are strikingly similar, making advances in either field applicable to the alternate discipline. Here, recent advances in understanding the roles of Semas in development and cancer, as well as the therapeutic potential for targeting this signaling pathway in human cancers, are reviewed.
Export Options
About this article
Cite this article as:
Flannery E. and Duman-Scheel M., Semaphorins at the Interface of Development and Cancer, Current Drug Targets 2009; 10 (7) . https://dx.doi.org/10.2174/138945009788680383
DOI https://dx.doi.org/10.2174/138945009788680383 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNAs-Based Therapeutic Strategy for Virally Induced Diseases
Current Drug Discovery Technologies Vascular Endothelial Growth Factor: Adaptive Changes in the Neuroglialvascular Unit
Current Neurovascular Research CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry Therapeutic Targeting of G-Protein Coupled Receptor-Mediated Epidermal Growth Factor Receptor Transactivation in Human Glioma Brain Tumors
Mini-Reviews in Medicinal Chemistry Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors
Current Medicinal Chemistry Magnetic Nanoparticles: New Players in Antimicrobial Peptide Therapeutics.
Current Protein & Peptide Science The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry Recovery of Locomotor Function with Combinatory Drug Treatments Designed to Synergistically Activate Specific Neuronal Networks
Current Medicinal Chemistry RAGE as a Receptor of HMGB1 (Amphoterin): Roles in Health and Disease
Current Molecular Medicine Nanodiamonds as a New Horizon for Pharmaceutical and Biomedical Applications
Current Drug Delivery Advances in Oncolytic Virus Therapy for Glioma
Recent Patents on CNS Drug Discovery (Discontinued) Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews microRNAs: Innovative Targets for Cerebral Ischemia and Stroke
Current Drug Targets Pharmacotherapeutic Potential of Garlic in Age-Related Neurological Disorders
CNS & Neurological Disorders - Drug Targets CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design